@article{5e77040df6804408a5afd9ba7835a470,
title = "Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes",
abstract = "We studied cancer-specifics outcomes of 25 patients with mucinous tubular and spindle-cell carcinoma of the kidney and we found that the most patients presented with localized tumor that were treated successfully with primary tumor-directed therapy. However, those with high-grade histological features were more likely to develop metastatic disease with limited responses to standard therapies.",
keywords = "Genomics, MTSCC, Non–clear-cell renal cell carcinoma, Survival, Systemic therapy",
author = "Yasser Ged and Chen, {Ying Bei} and Andrea Knezevic and Donoghue, {Mark T.A.} and Carlo, {Maria I.} and Lee, {Chung Han} and Feldman, {Darren R.} and Sujata Patil and Hakimi, {A. Ari} and Paul Russo and Voss, {Martin H.} and Motzer, {Robert J.}",
note = "Funding Information: Funding for this study was provided by Tuttle Rare Kidney Cancer Fund, Weiss Family Kidney Research Fund Precision, and Center Core Grant P30 CA008748 from the National Cancer Institute . Funding Information: Robert J. Motzer reports receiving commercial research grants from Pfizer, Eisai, Exelixis, Bristol-Myers Squibb, Genentech/Roche, and Novartis, and is a consultant/advisory board member for Pfizer, Merck, Genentech, Exelixis, Eisai, and Novartis. Martin H. Voss reports receiving commercial research grants from Bristol-Myers Squibb and Genentech/Roche, honoraria from Novartis, travel/accommodation from Eisai, Novartis, and Takeda, consultant/advisory board member for Alexion Pharmaceuticals, Bayer, Calithera Biosciences, Corvus Pharmaceuticals, Exelixis, Eisai, GlaxoSmithKline, Natera, Novartis, and Pfizer. Chung-Han Lee reports consulting/advisory role for Exelexis and Eisai. Maria I. Carlo reports consulting/advisory role for Pfizer. Darren R. Feldman reports research support from Novartis and Seattle Genetics. The remaining authors have stated that they have no conflicts of interest.Funding for this study was provided by Tuttle Rare Kidney Cancer Fund, Weiss Family Kidney Research Fund Precision, and Center Core Grant P30 CA008748 from the National Cancer Institute. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",
year = "2019",
month = aug,
doi = "10.1016/j.clgc.2019.04.006",
language = "English (US)",
volume = "17",
pages = "268--274.e1",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "4",
}